Introduction
============

Lung cancer is the primary cause of cancer-associated mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for \~85% of all lung cancer cases in 2014 ([@b1-ol-0-0-7328]). The majority of patients present with advanced disease with a 5-year survival rate of \<15% in 2014 ([@b2-ol-0-0-7328],[@b3-ol-0-0-7328]). Although surgery remains the front-line choice of treatment for localized NSCLC, those with advanced forms may require chemotherapy ([@b4-ol-0-0-7328]). Targeted therapy constitutes a promising treatment strategy for prolonging the survival of a subset of patients with NSCLC ([@b5-ol-0-0-7328]). However, drug resistance conferred by complex recurrent genetic and epigenetic changes remains a crucial obstacle for targeted therapies ([@b6-ol-0-0-7328]--[@b10-ol-0-0-7328]). Consequently, there is urgent requirement to understand the molecular mechanism(s) underlying the development of NSCLC, and develop new therapies for treating NSCLC.

Transforming growth factor β (TGFβ) regulator 4 (TBRG4), also termed cell cycle progression restoration protein 2 or Fas-activated serine-threonine kinase domain-containing protein 4, encodes a regulator for TGFb ([@b11-ol-0-0-7328]--[@b14-ol-0-0-7328]). *TBRG4* (GenBank no. AAH14918.1) is located on chromosome 7p12.3--13, and is duplicated in patients with Sézary syndrome ([@b15-ol-0-0-7328]). TBRG4 has previously been demonstrated to stabilize the expression level of transcription of cyclin 1 and 2 ([@b12-ol-0-0-7328]). In 293 and Jurkat human cell lines, TBRG4 physically interacts with the virus protein U encoded by the human immunodeficiency virus ([@b16-ol-0-0-7328]). Furthermore, TBRG4 also interacts with pleiotrophin protein, and *TBRG4* silencing affects the stability of certain mitochondrial mRNAs ([@b17-ol-0-0-7328],[@b18-ol-0-0-7328]). However, the contribution of *TBRG4* in the tumorigenesis of NSCLC remains unclear.

In the present study, the effect of *TBRG4* silencing on genome-wide gene expression patterns within human H1299 lung cancer cells was investigated. The expression of *TBRG4* in tumor and adjacent normal tissues was also evaluated.

Materials and methods
=====================

### Cell culture

Human H1299 lung cancer cells were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco\'s modified Eagle\'s medium (Corning Life Sciences, Shanghai, China) and supplemented with 10% fetal bovine serum (Sangon Biotech Co., Ltd., Shanghai, China) at 37°C in a humidified atmosphere containing 5% CO~2~.

### siRNA transduction

The sequence of siRNA (5′-GTTCTTCAGCCTGGTACAT-3′) was designed by GeneChem Co., Ltd. (Shanghai, China) for targeting the *TBRG4* sequence (GenBank no. NM_004749). The *TBRG4* hairpin oligonucleotide was inserted into the pGV115-GFP lentiviral vector (GeneChem Co., Ltd.) to construct a pGV115-GFP-short hairpin TBRG4 (shTBRG4) *TBRG4*-knockdown vector. The negative control (shCtrl) sequence was previously reported ([@b19-ol-0-0-7328],[@b20-ol-0-0-7328]), and when incorporated into the lentiviral vector was referred to as pGV115-GFP-shCtrl. The lentiviral particles were prepared as previously described ([@b21-ol-0-0-7328]). For cellular transduction of shTBRG4 lentiviral or shCtrl lentivirus, 1×10^5^ cells/well were seeded into 6-well plates. The following day, cells were transduced with validated shTBRG4 lentivirus (5×10^5^ TU/ml, 2 µl) or shCtrl lentivirus (8×10^5^ TU/ml, 1.25 µl) using 4 µl Lipofectamine 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer\'s protocol. After evaluating infection efficiency using light and fluorescent microscopy at 72 h after infection. Cells were harvested and used for subsequent experiments.

### RNA isolation and quantitative polymerase chain reaction (qPCR)

Total RNA was extracted from the aforementioned transduced cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and then 2 µg total RNA was reverse-transcribed using a QuantiTect reverse transcription kit (Qiagen China Co., Ltd., Shanghai, China), according to the manufacturer\'s protocol. A 1 µg amount of cDNA was used as a template for qPCR using a SYBR^®^ Green PCR Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The primer sequences used were as follows: *TBRG4* forward, 5′-CAGCTCACCTGGTAAAGCGAT-3′ and reverse, 5′-GGGAGTAGATGCTCGTTCCTTC-3′; *GAPDH* forward, 5′-TGACTTCAACAGCGACACCCA-3′ and reverse, 5′-CACCCTGTTGCTGTAGCCAAA-3′. Results were normalized to GAPDH data as described previously ([@b22-ol-0-0-7328]). Data were analyzed using the method of Pfaffl ([@b23-ol-0-0-7328]). PCR primers used for validating the microarray data are listed in [Table I](#tI-ol-0-0-7328){ref-type="table"}.

### Gene microarray

The genome-wide effect of TBRG4 knockdown was studied using a GeneChip^®^ PrimeView™ Human Gene Expression Array (Affymetrix; Thermo Fisher Scientific, Inc., Waltham, MA, USA) consisting of 20,000 genes. Three biological replicates of H1299 cells transduced with shTBRG4 or shCtrl lentiviruses (for 72 h) were microarrayed. RNA was initially isolated using TRIzol reagent, and quality was determined using a NanoDrop 2000 spectrophotometer (NanoDrop; Thermo Fisher Scientific, Inc., Wilmington, DE, USA) and Agilent Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA). Individual microarrays were used for gene expression profiling of each sample. Briefly, 500 ng total RNA was reverse-transcribed and labeled with biotin using the GeneChip^®^ 3′ IVT labeling kit, according to the manufacturer\'s protocol. Labeled cDNA was then hybridized onto the GeneChip^®^ PrimeView™ Human Gene Expression Array at 60°C overnight. Arrays were performed with GeneChip^®^ Hybridization Wash and Stain kit using GeneChip^®^ Fluidics Station 450. All GeneChip^®^ products were obtained from Affymetrix; Thermo Fisher Scientific, Inc., and all were used according to the manufacturer\'s protocol. The chip array was scanned directly post-hybridization using a GeneChip^®^ Scanner 3000. Microarray data were analyzed with GeneSpring software (version 11; Agilent Technologies, Inc.). Data were normalized using the GeneSpring normalization algorithm. Finally, genes which were differentially expressed \>1.5-fold, and had a differential score P≤0.05 among test samples, were identified from normalized data sets.

### Ingenuity pathway analysis (IPA)

Datasets representing differentially expressed genes derived from microarray analyses were imported into the IPA tool (<http://www.ingenuity.com>; Ingenuity^®^ Systems, Redwood City, CA, USA). The 'core analysis' function of the IPA software in the present study was used to interpret the differentially expressed data, which included 'Disease and Functions', and 'Molecular Network'. Differentially expressed genes were mapped onto genetic networks available in the Ingenuity database and then ranked on the basis of the overlap P-value to measure enrichment of network-regulated genes in the present dataset and the activation z-score algorithms computed by IPA software ([@b24-ol-0-0-7328]). Analyses performed within the IPA program include the identification of biological networks of a particular interesting dataset according to the purpose of the present study, and its global functions, functional signaling pathways and downstream target genes.

### Patients and tissue samples

A total of 75 patients diagnosed with lung cancer and who received surgery at The First Affiliated Hospital of Bengbu Medical College (Anhui, China) between December 2011 and June 2015 were randomly enrolled into the present study. All samples were obtained following provision of written informed consent and used with approval from the Review Board of The First Affiliated Hospital of Bengbu Medical College. The age range of diagnosed patients was between 35 and 77 years, with a median age of 60 years. Tissue samples were classified as tumor or adjacent carcinomatous tissue. Baseline characteristics of enrolled patients included age at time of diagnosis, tissue type, histological grade, distant metastasis and tumor-node-metastasis (TNM) stage ([Table II](#tII-ol-0-0-7328){ref-type="table"}). All patients were clinically staged according to the criteria of the American Joint Committee on Cancer staging system ([@b25-ol-0-0-7328]). Histological grades of primary tumors were based on the World Health Organization recommendations ([@b26-ol-0-0-7328]).

### Immunohistochemistry

Tissues were fixed in 4% neutral-buffered formalin at room temperature overnight and then embedded in paraffin. Sections of formalin-fixed paraffin-embedded sections (5 µm thick) were dehydrated and deparaffinized in xylene 2--3 times at room temperature and rehydrated with a gradient alcohol series. Antigen retrieval was performed using 0.1 mol/l citrate buffer (pH 6.0) at 95°C for 30 min. Endogenous peroxidase was quenched for 10 min with 3% (v/v) H~2~O~2~ at room temperature. Slides were then washed three times with PBS and blocked for 30 min with 10% (w/v) normal goat serum (Sangon Biotech Co., Ltd., Shanghai, China) in 1% (w/v) bovine serum albumin (Sangon Biotech Co., Ltd.) in PBS. Slides were incubated with a 1:1,000 dilution of anti-TBRG4 monoclonal antibody (cat. no. D154006; Sangon Biotech Co., Ltd.) at 37°C for 30 min. Following incubation for 1 h at room temperature with horseradish peroxidase-labeled streptavidin secondary antibody (dilution 1:1,000; cat. no. D111054; Sangon Biotech Co., Ltd.), the development reaction was detected by exposure to 3,3′-diaminobenzidine (Sangon Biotech Co., Ltd.) for 5 min at room temperature. Immunostained slides were digitized using the ScanScope XT (Aperio, Cista, CA, USA) and scored independently by two pathologists according to the Allred scoring system ([@b27-ol-0-0-7328]). The scoring was based on staining intensity: Negative, 0; weak, 1; intermediate, 2; and strong, 3. A proportionate score was assigned to represent the estimated percentage of positively stained cells (0, \<1%; 1, 1--25%; 2, 26--50%; 3, 51--75%; 4, ≥76%). The multiplication of the two parameters was performed to obtain a total score ranging from negative (0--1) to positive (\>2).

### Statistical analysis

Numerical data were expressed as the mean ± standard deviation, and analyzed using Student\'s t-test. All categorical data were expressed as a frequency. The Mann-Whitney U test was used to analyze the clinicopathological and *TBRG4* gene expression data. Analysis was performed with SPSS (version 16.0; SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Lentivirus-mediated TBRG4 knockdown

Efficacy of *TBRG4*-specific siRNA in downregulating the expression of *TBRG4* in H1299 lung cancer cells was evaluated with RNA expression data generated by qPCR. The proportions of infected H1299 cells transduced with either shCtrl or shTBRG4 lentiviruses were \>70% at 72 h post-infection ([Fig. 1A](#f1-ol-0-0-7328){ref-type="fig"}). The level of *TBRG4* mRNA expression in cells transduced with shTBRG4 was significantly decreased at 72 h post infection compared with those transduced with a shCtrl lentivirus (P\<0.01; [Fig. 1B](#f1-ol-0-0-7328){ref-type="fig"}). Thus, shTBRG4 lentivirus was specific and effective in knocking down *TBRG4*.

### Genome-wide effects of TBRG4 knockdown

In total, 20,000 genes were microarrayed to determine the influence that *TBRG4* knockdown has on downstream gene expression. The gene expression profiles of H1299 cells transduced with shTBRG4 or shCtrl-payload lentiviruses were determined using a GeneChip^®^ PrimeView™ Human Gene Expression Array using three biological replicates. A total of 586 differentially expressed genes were identified, of which 357 were downregulated and 229 were upregulated ([Fig. 2A](#f2-ol-0-0-7328){ref-type="fig"}).

### Elucidation of pathways and interactions among differentially expressed genes

Biological interactions were identified in the 586 differently regulated genes using the IPA program. This output highlighted 25 significant networks (data not shown), of which IPA identified a list of the top 10 networks ([Fig. 2B](#f2-ol-0-0-7328){ref-type="fig"}). Of these networks, those associated with infectious diseases, cancer, organismal injury and abnormalities were the *highest* ranked networks, with 27 focus molecules and a significance score of 42 ([Fig. 2C](#f2-ol-0-0-7328){ref-type="fig"}). In particular, [Fig. 2C](#f2-ol-0-0-7328){ref-type="fig"} presents that *TBRG4* is located upstream of all focus genes.

### TBRG4 knockdown markedly upregulates DDIT3 and downregulates CAV1 and RRM2

Expression of mRNA for 14 downstream genes of *TBRG4* identified using IPA was analyzed using qPCR, including *AURKA*, *CAV1*, *IGF2*, *MYBL2*, *RAP1A*, *CDC20*, *DDIT3*, *FOXM1*, *IDI1*, *PGK1*, *RRM3*, *SCD*, *SERPINE1* and *SESN2* ([Fig. 3A](#f3-ol-0-0-7328){ref-type="fig"}). Results demonstrated that *IGF2*, *RAP1A*, *DDIT3* and *SESN2* were upregulated following TBRG4 knockdown, whereas the remaining 10 genes were downregulated ([Fig. 3B](#f3-ol-0-0-7328){ref-type="fig"}). Western blotting also demonstrated that knockdown of *TBRG4* increased the level of DDIT3 expression and decreased the levels of CAV1 and RRM2 ([Fig. 3C and D](#f3-ol-0-0-7328){ref-type="fig"}).

### Association of TBRG4 expression in lung cancer tissues and clinicopathological characteristics

The present study immunostained the TBRG4 protein expressed within lung cancer and adjacent normal tissues. The immunohistochemical data revealed that the expression of TBRG4 was markedly increased within lung cancer tissues compared with normal tissues retrieved from the adjacent epithelium ([Fig. 4](#f4-ol-0-0-7328){ref-type="fig"}). There was no significant difference identified in TBRG4 expression between the sexes, neither was it significantly associated with age, tumor size, distant metastasis, TNM stage or tumor grade (P\>0.05; [Table II](#tII-ol-0-0-7328){ref-type="table"}).

Discussion
==========

*TBRG4* is implicated in a number of human malignancies; however, its contribution to lung cancer has not yet been evaluated. To the best of our knowledge, the present study is the first to investigate the expression of *TBRG4* within lung carcinomas. The results of the present study demonstrate that there is a markedly increased expression of *TBRG4* in lung cancer *in vitro* and *ex vivo*. As previously identified, *TBRG4* is a regulator of TGFb located on chromosome 7p12.7--13 ([@b15-ol-0-0-7328]). Chromosomal abnormity, including breakpoint and duplication at the 7p13 locus, has previously been reported in a range of hematological malignancies ([@b28-ol-0-0-7328]). Previously, it was reported that this region where *TBRG4* is located is disrupted in patients with Sézary syndrome, a leukemic form of cutaneous T-cell lymphoma, with chromosomal abnormalities and mutations in certain genes that are relevant to this disease ([@b14-ol-0-0-7328],[@b29-ol-0-0-7328]). The region is also amplified in 30% of cell lines derived from patients with head and neck squamous cell carcinoma ([@b30-ol-0-0-7328]). Furthermore, recent research has demonstrated that *TBRG4* exhibits significant changes in extramedullary relapse of multiple myelomas ([@b14-ol-0-0-7328]). This evidence suggests that *TBRG4* serves an important role in several types of human cancer.

In order to assess the contribution of *TBRG4* to lung cancer, a shTBRG4 lentiviral vector was initially constructed, which specifically silenced the expression of *TBRG4* in H1299 lung cancer cells. The shTBRG4-infected cells demonstrated a decrease in expression of *TBRG4* compared with those transduced with a shCtrl control lentivirus. In order to obtain an understanding of the downstream biological alterations, the transcriptome of H1299 cells transduced with either shTBRG4 or shCtrl lentiviruses was investigated with an Affymetrix microarray of 20,000 genes. Gene expression profiling and network analysis revealed a set of 586 differentially expressed genes, a number of which were categorized into infectious diseases, cancer, organismal injury and abnormalities. A key observation in the present study was the identification of the set of genes, which were altered downstream due to the knockdown of *TBRG4*. Results of the present study demonstrated a significant increase in the level of *DDIT3*, and a decrease in the levels of *CAV1* and *RRM2* genes at the transcriptional (qPCR) and translational (western blotting) levels. *DDIT3* is a transcription factor which is considered as a marker of commitment of endoplasmic reticulum stress-mediated apoptosis via induction of B-cell lymphoma 2 downregulation and death receptor 5 activation ([@b31-ol-0-0-7328],[@b32-ol-0-0-7328]). Caveolin-1 is a multifunctional molecule typically expressed in membranous structures. The wild-type form acts as a tumor suppressor protein through contact inhibition of signaling molecules; however, its loss in cancer cells promotes tumor growth, motility, vascularization and metastasis, and decreases survival outcomes ([@b33-ol-0-0-7328]--[@b36-ol-0-0-7328]). The ribonucleotide reductase subunit M2 (RRM2) is reported to regulate several oncogenes that control malignant potential, and therefore may serve a major role in tumor progression ([@b37-ol-0-0-7328],[@b38-ol-0-0-7328]). RRM2 serves as a prognostic biomarker for several types of cancer ([@b39-ol-0-0-7328]--[@b41-ol-0-0-7328]), and knockdown is reported to lead to apoptosis in NSCLC ([@b38-ol-0-0-7328]). Immunohistochemistry results validated the increased levels of TBRG4 in tumor tissue; therefore, *TBRG4* knockdown complicated the tumorigenesis of H1299 cells by upregulating *DDIT3* and downregulating *CAV1* and *RRM2*. Further study is currently ongoing in order to validate the precise role of *TBRG4* knockdown.

In conclusion, the results of the present study highlighted the tumorigenic roles of *TBRG4* by silencing its expression in human H1299 lung cancer cells. This present study has provided evidence to further the understanding of the precise role of *TBRG4* in the tumorigenesis of human lung cancer. However, the exact underlying molecular mechanisms by which TBRG4 influences the biological behaviors of lung cancer cells are yet to be determined.

![*TBRG4* knockdown in H1299 cells infected with shTBRG4 lentivirus. H1299 cells were infected with the shTBRG4 or shCtrl lentivirus. (A) Infection efficiency evaluated using light and fluorescent microscopy at 72 h post infection. Representative images of the cultures are presented (magnification, ×100). (B) Results represent the fold change in *TBRG4* mRNA levels, normalized to *GAPDH* expression. \*\*P\<0.01, compared with the shCtrl group. sh, short hairpin; Ctrl, control; TBRG4, transforming growth factor β regulator 4.](ol-15-01-0121-g00){#f1-ol-0-0-7328}

![IPA summary of differentially expressed genes derived from a microarray of 20,000 genes. (A) Heat map of differentially expressed genes derived from microarray. (B) Top 10 networks with their respective scores obtained using IPA. (C) The highest rated networks (infectious diseases, cancer, organismal injury and abnormalities) in IPA. Upregulated genes are depicted in red, whereas downregulated genes are depicted in green. IPA, Ingenuity Pathway Analysis; sh, short hairpin; Ctrl, control; TBRG4, transforming growth factor β regulator 4.](ol-15-01-0121-g01){#f2-ol-0-0-7328}

![Effect of TBRG4 knockdown on downstream genes. (A) Analysis of downstream genes of TBRG4 using IPA. (B) qPCR was used to determine the changes in expression level of downstream genes of TBRG4 in H1299 cells 72 h after transfection of TBRG4-specific siRNA. Samples were normalized to GAPDH mRNA expression. The qPCR data are expressed as the mean ± standard deviation of three independent experiments performed in triplicate. (C) Western blotting was performed to analyze the change in expression of TBRG4 downstream proteins in H1299 cells infected with shTBRG4 lentivirus. (D) Densitometric analysis of target proteins in (C). GAPDH protein was used as a loading control for densitometric analysis. \*\*P\<0.05 vs. shCtrl-transfected cells. IPA, Ingenuity Pathway Analysis; qPCR, quantitative polymerase chain reaction; siRNA, small interfering RNA; sh, short hairpin; Ctrl, control; TBRG4, transforming growth factor β regulator 4.](ol-15-01-0121-g02){#f3-ol-0-0-7328}

![Representative images of TBRG4 protein expression in lung tumor and cancer-adjacent normal tissue by immunohistochemisty. Magnification, ×200 (insets, ×40).](ol-15-01-0121-g03){#f4-ol-0-0-7328}

###### 

Primer sequences used for quantitative polymerase chain reaction.

  Gene            Primer sequence 5′-3′
  --------------- -------------------------
  *GAPDH* FP      TGACTTCAACAGCGACACCCA
  *GAPDH* RP      CACCCTGTTGCTGTAGCCAAA
  *IGF2* FP       CCTCCAGTTCGTCTGTGGG
  *IGF2* RP       CACGTCCCTCTCGGACTTG
  *MYBL2* FP      AGAATAGCACCAGTCTGTCCTT
  *MYBL2* RP      CCAATGTGTCCTGTTTGTTCCA
  *AURKA* FP      GCCCTGTCTTACTGTCATTCG
  *AURKA* RP      AGGTCTCTTGGTATGTGTTTGC
  *CAV1* FP       CTGAGCGAGAAGCAAGTG
  *CAV1* RP       AGAGAGAATGGCGAAGTAAATG
  *RAP1A* FP      CGTGAGTACAAGCTAGTGGTCC
  *RAP1A* RP      CCAGGATTTCGAGCATACACTG
  *SERPINE1* FP   GCACCACAGACGCGATCTT
  *SERPINE1* RP   ACCTCTGAAAAGTCCACTTGC
  *SCD* FP        TACTTGGAAGACGACATTCGC
  *SCD* RP        GGTGTAGAACTTGCAGGTAGGA
  *DDIT3* FP      CTTCTCTGGCTTGGCTGACTGA
  *DDIT3* RP      TGACTGGAATCTGGAGAGTGAGG
  *SESN2* FP      TCTTACCTGGTAGGCTCCCAC
  *SESN2* RP      AGCAACTTGTTGATCTCGCTG
  *RRM2* FP       AAGAAACGAGGACTGATGC
  *RRM2* RP       CTGTCTGCCACAAACTCAA
  *CDC20* FP      CTTCGGCTCAGTGGAAAA
  *CDC20* RP      GTCTGGCAGGGAAGGAAT
  *FOXM1* FP      GCAGCGACAGGTTAAGGTTGAG
  *FOXM1* RP      GTTGTGGCGGATGGAGTTCTTC
  *IDI1* FP       TCCATTAAGCAATCCAGCCGA
  *IDI1* RP       CCCAGATACCATCAGACTGAGC
  *PGK1* FP       TGGACGTTAAAGGGAAGCGG
  *PGK1* RP       GCTCATAAGGACTACCGACTTGG

FP, forward primer; RP, reverse primer.

###### 

Association of TBRG4 expression and clinicopathological characteristics.

                             *TBRG4*         
  -------------------- ----- --------- ----- ----------------------------------------------------
  Sex                                        0.808
    Male               39    31          8   
    Female             35    27          8   
  Age, years                                 0.348
    ≤60                34    28          6   
    \>60               41    30        11    
  Tumor size, cm                             0.698
    ≤4                 50    38        12    
    \>4                25    20          5   
  Distant metastasis                         0.269
    M0                 71    54        17    
    M1                   4     4         0   
  TNM stage                                  0.014^[a](#tfn2-ol-0-0-7328){ref-type="table-fn"}^
    TNM1               37    24        13    
    TNM2               18    16          2   
    TNM3               16    14          2   
    TNM4                 4     4         0   
  Tumor grade                                
    I/II               53    40        13    0.553
    III                22    18          4   

P-value for the TNM stage was corrected for multiple comparison by the Bonferroni correction method. P=0.014 was not considered to indicate a statistically significant difference according to the principle of multiple testing of Bonferroni correction. TNM, tumor-node-metastasis.
